Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic

Oncologist

Volumn 16, Issue 3, 2011, Pages 327-335

  Janku, Filip ^a   Tsimberidou, Apostolia M ^a   Wang, Xuemei ^a   Hong, David S ^a   Naing, Aung ^a   Gong, Jing ^a   Garrido Laguna, Ignacio ^a   Parsons, Henrique A ^a   Zinner, Ralph G ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Non small cell lung cancer; Phase I; Survival

Indexed keywords

ANGIOPOIETIN INHIBITOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEMCITABINE; HEMOGLOBIN; IMEXON; PACLITAXEL; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADULT; ADVANCED CANCER; AGED; CONTROLLED STUDY; DEATH; DRUG RESPONSE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SMOKING; SURVIVAL TIME; SYSTEMIC THERAPY; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79953004809     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0308     Document Type: Review

References (54)

1. National Cancer Institute. SEER Cancer Statistics Review 1975-2006. Estimated New Cancer Cases and Deaths for 2009. Available at http://www.seer.cancer.gov/csr/1975_2006/results_single/sect_01_table.01.pdf, accessed November 29, 2010.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359:1367-1380.
3. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625.
4. Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995;71:366-370.
5. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
6. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
8. Higgins MJ, Ettinger DS. Chemotherapy for lung cancer: The state of the art in 2009. Expert Rev Anticancer Ther 2009;9:1365-1378.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
10. Ratain MJ, Eisen T, StadlerWM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512.
11. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf, accessed February 4, 2010.
12. Kaplan EM, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc 1958;53:457-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
14. Cox D. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol 1972;34:187-220.
15. Bahleda RF, Herbst E, Hanna RS et al. Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer. J Clin Oncol 2008;26:Abstract 2564.
16. LoRusso PH, Heath D, Kurzrock E et al. First-in-human study ofAMG655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. J Clin Oncol 2007;25:Abstract 3534.
17. Rosen LS, Kurzrock R, Mulay M et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:2369-2376.
18. Johnson FM, Agrawal S, Burris H et al. Phase 1 pharmacokinetic and druginteraction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-1591.
19. Camidge DH, Gordon RS, Eckhardt M et al. A phase I safety and pharmacokinetic study of apomab, a human DR5 agonist antibody, in patients with advanced cancer. J Clin Oncol 2007;25:Abstract 3582.
20. Tsimberidou AM, Camacho LH, Verstovsek S et al. A phase I clinical trial of darinaparsin in patients with refractory solid tumors. Clin Cancer Res 2009;15:4769-4776.
21. Herbst RS, Hong D, Chap L et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009;27:3557-3565.
22. Kurzrock RA, Hong W, Ng D et al. Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases. J Clin Oncol 2007;25:Abstract 3604.
23. Stephenson JL, Martin N, Ho JC et al. Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies. J Clin Oncol 2008;26:Abstract 2516.
24. Moulder S, Dhillon N, Ng C et al. A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer. Invest New Drugs 2010;28: 634-640.
25. Heath EB, Cohen GR, LoRusso RB et al. Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. J Clin Oncol 2009;27:Abstract e14509.
26. Falchook GD, Moulder N, Duvic S et al. Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies. J Clin Oncol 2007;25:Abstract 14087
27. Itoh K, Sasaki Y, Miyata Y et al. Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol 1994;34:451-454.
28. Decoster G, Stein G, Holdener EE. Responses and toxic deaths in phase I clinical trials. Ann Oncol 1990;1:175-181.
29. Horstmann E, McCabe MS, Grochow L et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005;352:895-904.
30. Kurzrock R, Benjamin RS. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 2005;352:930-932.
31. Jain RK, Lee JJ, Hong D et al. Phase I oncology studies: Evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 2010;16:1289-1297.
32. Adjei AA, Molina JR, Mandrekar SJ et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007;13:2684-2691.
33. Baas P, Szczesna A, Albert I et al. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. J Thorac Oncol 2008;3:745-750.
34. Borghaei H, Alpaugh K, Hedlund G et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:4116-4123.
35. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001;19: 851-856.
36. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
37. Haura EB, Tanvetyanon T, Chiappori A et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-smallcell lung cancer. J Clin Oncol 2010;28:1387-1394.
38. Thienelt CD, Bunn PA Jr, Hanna N et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23:8786-8793.
39. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-98.
40. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
41. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
42. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
43. Arkenau HT, Olmos D, Ang JE et al. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital experience. Br J Cancer 2008;98:1029-1033.
44. Wheler J, Tsimberidou AM, Hong D et al. Survival of patients in a phase 1 clinic: The M. D. Anderson Cancer Center experience. Cancer 2009;115: 1091-1099.
45. Tsimberidou AM, Vaklavas C, Wen S et al. Phase I clinical trials in 56 patients with thyroid cancer: The M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab 2009;94:4423-4432.
46. Bachelot T, Ray-Coquard I, Catimel G et al. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000;11:151-156.
47. Han C, Braybrooke JP, Deplanque G et al. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 2003;89:1166-1171.
48. Garrido-Laguna I, Janku F, Falchook GS et al. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res 2010;16:4031-4037.
49. Arkenau HT, Barriuso J, Olmos D et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009;27:2692-2696.
50. Roberts TG Jr, Goulart BH, Squitieri L et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 2004; 292:2130-2140.
51. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
52. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
53. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med;363:1693-703.
54. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-414